{"protocolSection": {"identificationModule": {"nctId": "NCT01704495", "orgStudyIdInfo": {"id": "D3551C00001"}, "secondaryIdInfos": [{"id": "2012-001869-33"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.", "officialTitle": "A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study With an Optional Safety Extension Treatment Period up to 6 Months, to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting \u03b22 Agonists (LABA), in Patients With Uncontrolled Persistent Asthma", "acronym": "NIMBUS"}, "statusModule": {"statusVerifiedDate": "2016-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-11"}, "primaryCompletionDateStruct": {"date": "2014-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-10-09", "studyFirstSubmitQcDate": "2012-10-09", "studyFirstPostDateStruct": {"date": "2012-10-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-06-30", "resultsFirstSubmitQcDate": "2016-02-01", "resultsFirstPostDateStruct": {"date": "2016-03-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-02-01", "lastUpdatePostDateStruct": {"date": "2016-03-01", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose is to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting \u03b22 Agonists (LABA), in Patients with Uncontrolled Persistent Asthma", "detailedDescription": "A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study with an Optional Safety Extension Treatment Period up to 6 months, to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting \u03b22 Agonists (LABA), in Patients with Uncontrolled Persistent Asthma"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Uncontrolled Asthma,", "Exacerbation,", "Safety"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1147, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "AZD5069 5 mg", "type": "EXPERIMENTAL", "description": "AZD5069 oral capsules self-administered twice daily", "interventionNames": ["Drug: AZD5069"]}, {"label": "AZD5069 15 mg", "type": "EXPERIMENTAL", "description": "AZD5069 oral capsules self-administered twice daily", "interventionNames": ["Drug: AZD5069"]}, {"label": "AZD5069 45 mg", "type": "EXPERIMENTAL", "description": "AZD5069 oral capsules self-administered twice daily", "interventionNames": ["Drug: AZD5069"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo oral capsules self-administered twice daily", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "AZD5069", "description": "AZD5069 oral capsules self-administered twice daily.", "armGroupLabels": ["AZD5069 15 mg", "AZD5069 45 mg", "AZD5069 5 mg"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo oral capsules self-administered twice daily.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Rate of Severe Asthma Exacerbations During 6 Months", "timeFrame": "From start of treatment up to 6 months"}], "secondaryOutcomes": [{"measure": "Rate of Asthma-specific Hospital Admission/Intensive Care Unit Admissions During 6 Months", "timeFrame": "From start of treatment up to 6 months"}, {"measure": "Total Number of Days of Asthma-specific Hospital Admission/Intensive Care Unit Admissions", "timeFrame": "From start of treatment up to 6 months"}, {"measure": "Total Number of Days on Oral Cortecosteroids, Due to a Worsening of Asthma Symptoms", "timeFrame": "From start of treatment up to 6 months"}, {"measure": "Change From Baseline to 2 Weeks Measurement of Pre-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at two weeks are included in the analysis", "timeFrame": "Baseline (Day 0) and 2 weeks after Day 0"}, {"measure": "Change From Baseline to 1 Month Measurement of Pre-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at one month are included in the analysis", "timeFrame": "Baseline (Day 0) and 1 month after Day 0"}, {"measure": "Change From Baseline to 2 Months Measurement of Pre-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at two months are included in the analysis", "timeFrame": "Baseline (Day 0) and 2 months after Day 0"}, {"measure": "Change From Baseline to 3 Months Measurement of Pre-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at three months are included in the analysis", "timeFrame": "Baseline (Day 0) and 3 months after Day 0"}, {"measure": "Change From Baseline to 4 Months Measurement of Pre-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at four months are included in the analysis", "timeFrame": "Baseline (Day 0) and 4 months after Day 0"}, {"measure": "Change From Baseline to 6 Months Measurement of Pre-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at six months are included in the analysis", "timeFrame": "Baseline (Day 0) and 6 months after Day 0"}, {"measure": "Change From Baseline to 2 Weeks Measurement of Post-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at two weeks are included in the analysis", "timeFrame": "Baseline (Day 0) and 2 weeks after Day 0"}, {"measure": "Change From Baseline to 1 Month Measurement of Post-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at one month are included in the analysis", "timeFrame": "Baseline (Day 0) and 1 month after Day 0"}, {"measure": "Change From Baseline to 2 Months Measurement of Post-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at two months are included in the analysis", "timeFrame": "Baseline (Day 0) and 2 months after Day 0"}, {"measure": "Change From Baseline to 3 Months Measurement of Post-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at three months are included in the analysis", "timeFrame": "Baseline (Day 0) and 3 months after Day 0"}, {"measure": "Change From Baseline to 4 Months Measurement of Post-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at four months are included in the analysis", "timeFrame": "Baseline (Day 0) and 4 months after Day 0"}, {"measure": "Change From Baseline to 6 Months Measurement of Post-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at six months are included in the analysis", "timeFrame": "Baseline (Day 0) and 6 months after Day 0"}, {"measure": "Change From Baseline to Overall Mean of Treatment Period in ACQ-5 (Asthma Control Questionnaire, 5-item Version) Total Score", "description": "The ACQ-5 is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze. Each item is graded on a scale of 0-6 and the questions are equally weighted. The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).", "timeFrame": "Baseline (Day 0), Treatment Period (1,2,3,4, and 6 months)"}, {"measure": "Number of Patients Presenting Improvement From Baseline to End of Treatment Period in ACQ-5 (Asthma Control Questionnaire, 5-item Version)", "description": "The ACQ-5 is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze. Each item is graded on a scale of 0-6 and the questions are equally weighted. The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).", "timeFrame": "Baseline (Day 0) and 6 months after Day 0"}, {"measure": "Change From Baseline to Overall Mean of Treatment Period in AQLQ(S) (Asthma Quality of Life Questionnaire Standardised Version) Overall Score", "description": "The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments in asthma. Patients are asked to score each item on a 7-point scale based on the experience of last 2 weeks. The overall AQLQ score is the mean response to all 32 questions. Therefore, the possible highest score (better) would be 7 and the lowest (worse) would be 1. Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and \\> 1.5 as marked clinically important differences for any individual domain or for the overall summary score.", "timeFrame": "Baseline (Day 0), Treatment Period (1,3, and 6 months)"}, {"measure": "Number of Patients Presenting Improvement From Baseline to End of Treatment Period in AQLQ(S) (Asthma Quality of Life Questionnaire Standardised Version) Overall Score", "description": "The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments in asthma. Patients are asked to score each item on a 7-point scale based on the experience of last 2 weeks. The overall AQLQ score is the mean response to all 32 questions. Therefore, the possible highest score (better) would be 7 and the lowest (worse) would be 1. Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and \\> 1.5 as marked clinically important differences for any individual domain or for the overall summary score.", "timeFrame": "Baseline (Day 0) and 6 months after Day 0"}, {"measure": "Change From Baseline to Treatment Period (Day 1 to Day 28) for Astma Symptom Free Days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 1 to 28)"}, {"measure": "Change From Baseline to Treatment Period (Day 29 to Day 56) for Astma Symptom Free Days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 29 to 56)"}, {"measure": "Change From Baseline to Treatment Period (Day 57 to Day 84) for Asthma Symptom Free Days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 57 to 84)"}, {"measure": "Change From Baseline to Treatment Period (Day 85 to End of Treatment [6 Months]) for Asthma Symptom Free Days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Day 85 to 6 months)"}, {"measure": "Change From Baseline to Treatment Period (Day 1 to Day 28) for Asthma Control Days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 1 to 28)"}, {"measure": "Change From Baseline to Treatment Period (Day 29 to Day 56) for Asthma Control Days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 29 to 56)"}, {"measure": "Change From Baseline to Treatment Period (Day 57 to Day 84) for Asthma Control Days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 57 to 84)"}, {"measure": "Change From Baseline to Treatment Period (Day 85 to End of Treatment [6 Months]) for Asthma Control Days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 85 to 6 months"}, {"measure": "Change From Baseline to Treatment Period (Day 1 to Day 28) for Use of Rescue Medication Free Days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 1 to 28)"}, {"measure": "Change From Baseline to Treatment Period (Day 29 to Day 56) for Use of Rescue Medication Free Days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 29 to 56)"}, {"measure": "Change From Baseline to Treatment Period (Day 57 to Day 84) for Use of Rescue Medication Free Days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 57 to 84)"}, {"measure": "Change From Baseline to Treatment Period (Day 85 to End of Treatment [6 Months]) for Use of Rescue Medication Free Days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 85 to 6 months)"}, {"measure": "Change From Baseline to Treatment Period (Day 1 to Day 28) for Night Time Awakenings Due to Asthma Symptoms", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 1 to 28)"}, {"measure": "Change From Baseline to Treatment Period (Day 29 to Day 56) for Night Time Awakenings Due to Asthma Symptoms", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Day 29 to Day 56)"}, {"measure": "Change From Baseline to Treatment Period (Day 57 to Day 84) for Night Time Awakenings Due to Asthma Symptoms", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Day 57 to Day 84)"}, {"measure": "Change From Baseline to Treatment Period (Day 85 to End of Treatment [6 Months]) for Night Time Awakenings Due to Asthma Symptoms", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Day 85 to 6 months)"}, {"measure": "Number of Participants With Well Controlled Asthma Weeks at Baseline", "timeFrame": "Last 2 weeks before randomization"}, {"measure": "Number of Well Controlled Asthma Weeks During Treatment", "timeFrame": "Day 1to end of the 6 months treatment period"}, {"measure": "Number of Participants With Uncontrolled Persistent Asthma Weeks at Baseline", "timeFrame": "Last 2 weeks before randomization"}, {"measure": "Number of Uncontrolled Persistent Asthma Weeks During Treatment", "timeFrame": "Day 1 to end of the 6 months treatment period"}, {"measure": "Mean Plasma Concentration of AZD5069 at Day 7", "timeFrame": "Day 7"}, {"measure": "Mean Plasma Concentration of AZD5069 at 1 Month", "timeFrame": "at 1 month"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Men and women aged 18 years and above. Females of childbearing potential must use a highly effective contraceptive method plus a condom by their male partner.\n* Diagnosis of asthma for at least 12 months (GINA 2011)\n* Uncontrolled persistent asthma, despite treatment with medium to high dose ICS and LABA, and with a history of exacerbations during the last year\n* Morning prebronchodilator FEV1 of \u226530% and \u226485% predicted normal at enrolment\n* Daily use of medium or high dose ICS (\u2265fluticasone 500 \u00b5g or the equivalent daily)\n\nExclusion Criteria:\n\n* Any clinically significant disease or disorder (including any chronic lower respiratory disease other than asthma) that may put the patient at risk or influence study results\n* Patients with recurrent, latent, or chronic infections\n* Active tuberculosis or latent tuberculosis without completion of an appropriate course of treatment or prophylactic treatment\n* Significant lower respiratory tract infection not resolved within 30 days prior to enrolment\n* Current smoker or smoking history of more than 20 pack years", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "150 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bengt Larsson, MEDICAL SCIENCE DIRECTOR", "affiliation": "AZ Mondal R&D, Sweden", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Gotse Delchev", "country": "Bulgaria", "geoPoint": {"lat": 41.56667, "lon": 23.73333}}, {"facility": "Research Site", "city": "Kozloduy", "country": "Bulgaria", "geoPoint": {"lat": 43.77867, "lon": 23.72067}}, {"facility": "Research Site", "city": "Petrich", "country": "Bulgaria", "geoPoint": {"lat": 41.39847, "lon": 23.20705}}, {"facility": "Research Site", "city": "Pleven", "country": "Bulgaria", "geoPoint": {"lat": 43.41667, "lon": 24.61667}}, {"facility": "Research Site", "city": "Razgrad", "country": "Bulgaria", "geoPoint": {"lat": 43.53333, "lon": 26.51667}}, {"facility": "Research Site", "city": "Ruse", "country": "Bulgaria", "geoPoint": {"lat": 43.85639, "lon": 25.97083}}, {"facility": "Research Site", "city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Research Site", "city": "Vidin", "country": "Bulgaria", "geoPoint": {"lat": 43.99, "lon": 22.8725}}, {"facility": "Research Site", "city": "Mount Pearl", "state": "Newfoundland and Labrador", "country": "Canada", "geoPoint": {"lat": 47.51659, "lon": -52.78135}}, {"facility": "Research Site", "city": "Hamilton", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Research Site", "city": "Toronto", "state": "Ontario", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "Saint-Romuald", "state": "Quebec", "country": "Canada", "geoPoint": {"lat": 46.75818, "lon": -71.23921}}, {"facility": "Research Site", "city": "Quebec", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Brno", "country": "Czech Republic", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "Research Site", "city": "Jindrichuv Hradec", "country": "Czech Republic", "geoPoint": {"lat": 49.14404, "lon": 15.00301}}, {"facility": "Research Site", "city": "Karlovy Vary", "country": "Czech Republic", "geoPoint": {"lat": 50.23271, "lon": 12.87117}}, {"facility": "Research Site", "city": "Kutna Hora", "country": "Czech Republic", "geoPoint": {"lat": 49.94839, "lon": 15.26816}}, {"facility": "Research Site", "city": "Melnik", "country": "Czech Republic", "geoPoint": {"lat": 50.3505, "lon": 14.47411}}, {"facility": "Research Site", "city": "Praha 5", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Research Site", "city": "Praha 6", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Research Site", "city": "Strakonice", "country": "Czech Republic", "geoPoint": {"lat": 49.26141, "lon": 13.90237}}, {"facility": "Research Site", "city": "Tabor", "country": "Czech Republic", "geoPoint": {"lat": 49.41441, "lon": 14.6578}}, {"facility": "Research Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Gro\u00dfhansdorf", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}, {"facility": "Research Site", "city": "Hamburg", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Research Site", "city": "Hannover", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Research Site", "city": "M\u00fcnchen", "country": "Germany", "geoPoint": {"lat": 48.13743, "lon": 11.57549}}, {"facility": "Research Site", "city": "Asz\u00f3d", "country": "Hungary", "geoPoint": {"lat": 47.65174, "lon": 19.4785}}, {"facility": "Research Site", "city": "Baja", "country": "Hungary", "geoPoint": {"lat": 46.17496, "lon": 18.95639}}, {"facility": "Research Site", "city": "Balassagyarmat", "country": "Hungary", "geoPoint": {"lat": 48.07296, "lon": 19.29614}}, {"facility": "Research Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Cegl\u00e9d", "country": "Hungary", "geoPoint": {"lat": 47.17266, "lon": 19.79952}}, {"facility": "Research Site", "city": "Gyula", "country": "Hungary", "geoPoint": {"lat": 46.65, "lon": 21.28333}}, {"facility": "Research Site", "city": "Kom\u00e1rom", "country": "Hungary", "geoPoint": {"lat": 47.74318, "lon": 18.11913}}, {"facility": "Research Site", "city": "Mak\u00f3", "country": "Hungary", "geoPoint": {"lat": 46.21667, "lon": 20.48333}}, {"facility": "Research Site", "city": "Monor", "country": "Hungary", "geoPoint": {"lat": 47.35133, "lon": 19.44733}}, {"facility": "Research Site", "city": "Ny\u00edregyh\u00e1za", "country": "Hungary", "geoPoint": {"lat": 47.95539, "lon": 21.71671}}, {"facility": "Research Site", "city": "P\u00e9cs", "country": "Hungary", "geoPoint": {"lat": 46.08333, "lon": 18.23333}}, {"facility": "Research Site", "city": "Szeged", "country": "Hungary", "geoPoint": {"lat": 46.253, "lon": 20.14824}}, {"facility": "Research Site", "city": "Szombathely", "country": "Hungary", "geoPoint": {"lat": 47.23088, "lon": 16.62155}}, {"facility": "Research Site", "city": "Sz\u00e1zhalombatta", "country": "Hungary", "geoPoint": {"lat": 47.32579, "lon": 18.92141}}, {"facility": "Research Site", "city": "Guadalajara", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Research Site", "city": "Mexico", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Research Site", "city": "Monterrey", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Research Site", "city": "Bia\u0142ystok", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Research Site", "city": "Gda\u0144sk", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "Research Site", "city": "Gi\u017cycko", "country": "Poland", "geoPoint": {"lat": 54.03811, "lon": 21.76441}}, {"facility": "Research Site", "city": "Krak\u00f3w", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Lublin", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "Research Site", "city": "Pozna\u0144", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Research Site", "city": "Proszowice", "country": "Poland", "geoPoint": {"lat": 50.19275, "lon": 20.28909}}, {"facility": "Research Site", "city": "Skierniewice", "country": "Poland", "geoPoint": {"lat": 51.95485, "lon": 20.15837}}, {"facility": "Research Site", "city": "Tarn\u00f3w", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "Research Site", "city": "Wroc\u0142aw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "\u0141\u00f3d\u017a", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Research Site", "city": "\u017bnin", "country": "Poland", "geoPoint": {"lat": 52.84958, "lon": 17.71992}}, {"facility": "Research Site", "city": "Brasov", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Research Site", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Research Site", "city": "Constanta", "country": "Romania", "geoPoint": {"lat": 44.18073, "lon": 28.63432}}, {"facility": "Research Site", "city": "Deva", "country": "Romania", "geoPoint": {"lat": 45.88333, "lon": 22.9}}, {"facility": "Research Site", "city": "Iasi", "country": "Romania", "geoPoint": {"lat": 47.16667, "lon": 27.6}}, {"facility": "Research Site", "city": "Ekaterinburg", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "Research Site", "city": "Izhevsk", "country": "Russian Federation", "geoPoint": {"lat": 56.84976, "lon": 53.20448}}, {"facility": "Research Site", "city": "Kazan", "country": "Russian Federation", "geoPoint": {"lat": 55.78874, "lon": 49.12214}}, {"facility": "Research Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Saint Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Saint-Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Vladikavkaz", "country": "Russian Federation", "geoPoint": {"lat": 43.03667, "lon": 44.66778}}, {"facility": "Research Site", "city": "Yaroslavl", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Research Site", "city": "Bardejov", "country": "Slovakia", "geoPoint": {"lat": 49.29175, "lon": 21.27271}}, {"facility": "Research Site", "city": "Bratislava", "country": "Slovakia", "geoPoint": {"lat": 48.14816, "lon": 17.10674}}, {"facility": "Research Site", "city": "Komarno", "country": "Slovakia", "geoPoint": {"lat": 47.76356, "lon": 18.12263}}, {"facility": "Research Site", "city": "Kosice", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"facility": "Research Site", "city": "Levice", "country": "Slovakia", "geoPoint": {"lat": 48.21563, "lon": 18.60705}}, {"facility": "Research Site", "city": "Poprad", "country": "Slovakia", "geoPoint": {"lat": 49.06144, "lon": 20.29798}}, {"facility": "Research Site", "city": "Spisska Nova Ves", "country": "Slovakia", "geoPoint": {"lat": 48.94464, "lon": 20.56153}}, {"facility": "Research Site", "city": "Surany", "country": "Slovakia", "geoPoint": {"lat": 48.08613, "lon": 18.18447}}, {"facility": "Research Site", "city": "Topolcany", "country": "Slovakia", "geoPoint": {"lat": 48.56361, "lon": 18.16712}}, {"facility": "Research Site", "city": "Trencin", "country": "Slovakia", "geoPoint": {"lat": 48.89452, "lon": 18.04436}}, {"facility": "Research Site", "city": "Zvolen", "country": "Slovakia", "geoPoint": {"lat": 48.57442, "lon": 19.15324}}, {"facility": "Research Site", "city": "Amanzimtoti", "country": "South Africa", "geoPoint": {"lat": -30.05219, "lon": 30.88527}}, {"facility": "Research Site", "city": "Cape Town", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Research Site", "city": "Durban", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Research Site", "city": "Pretoria", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"facility": "Research Site", "city": "Umkomaas", "country": "South Africa", "geoPoint": {"lat": -30.20674, "lon": 30.79776}}, {"facility": "Research Site", "city": "Donetsk", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "Research Site", "city": "Ivano-Frankivsk", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Research Site", "city": "Kharkiv", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Research Site", "city": "Kyiv", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Research Site", "city": "Vinnytsia", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "Research Site", "city": "Zaporizhzhya", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"facility": "Research Site", "city": "Zaporizhzhzya", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"facility": "Research Site", "city": "Zaporozye", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"facility": "Research Site", "city": "Birmingham", "country": "United Kingdom", "geoPoint": {"lat": 52.48142, "lon": -1.89983}}, {"facility": "Research Site", "city": "Dundee", "country": "United Kingdom", "geoPoint": {"lat": 56.46913, "lon": -2.97489}}, {"facility": "Research Site", "city": "Liverpool", "country": "United Kingdom", "geoPoint": {"lat": 53.41058, "lon": -2.97794}}, {"facility": "Research Site", "city": "London", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}]}, "referencesModule": {"references": [{"pmid": "27574788", "type": "DERIVED", "citation": "O'Byrne PM, Metev H, Puu M, Richter K, Keen C, Uddin M, Larsson B, Cullberg M, Nair P. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016 Oct;4(10):797-806. doi: 10.1016/S2213-2600(16)30227-2. Epub 2016 Aug 27."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "4 weeks run-in period on background therapy prior to randomization.\n\nThe discrepancy in the number of enrolled patients compared to the protocol section (n=1147) is because of a patient was in error reported by a monitor as enrolled when the patient was in effect not enrolled.", "recruitmentDetails": "6 months double-blind study with optional safety extension for up to 6 months, were subjects continued on the treatment they were randomized to. First subject enrolled 27 Nov 2012 Last subject last visit 27 Aug 2014 1146 subjects enrolled in tot of which 506 patients were not randomized since they did not fulfilled all the inclusion conditions.", "groups": [{"id": "FG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "FG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "FG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "FG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "periods": [{"title": "Subjects Randomized", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "162"}, {"groupId": "FG001", "numSubjects": "156"}, {"groupId": "FG002", "numSubjects": "160"}, {"groupId": "FG003", "numSubjects": "162"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "140"}, {"groupId": "FG001", "numSubjects": "141"}, {"groupId": "FG002", "numSubjects": "144"}, {"groupId": "FG003", "numSubjects": "145"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "16"}, {"groupId": "FG003", "numSubjects": "17"}]}], "dropWithdraws": [{"type": "Other Reason", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Discontinuation criteria met", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Eligibility criteria not fulfilled", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "3"}]}]}, {"title": "Optional Safety Extension", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "46 subjects did not enter safety extension", "numSubjects": "116"}, {"groupId": "FG001", "comment": "35 subjects did not enter safety extension", "numSubjects": "121"}, {"groupId": "FG002", "comment": "46 subjects did not enter safety extension", "numSubjects": "114"}, {"groupId": "FG003", "comment": "46 subjects did not enter safety extension", "numSubjects": "116"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "87"}, {"groupId": "FG001", "numSubjects": "88"}, {"groupId": "FG002", "numSubjects": "83"}, {"groupId": "FG003", "numSubjects": "85"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "29"}, {"groupId": "FG001", "numSubjects": "33"}, {"groupId": "FG002", "numSubjects": "31"}, {"groupId": "FG003", "numSubjects": "31"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Other reason", "reasons": [{"groupId": "FG000", "numSubjects": "27"}, {"groupId": "FG001", "numSubjects": "29"}, {"groupId": "FG002", "numSubjects": "30"}, {"groupId": "FG003", "numSubjects": "28"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "BG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "BG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "BG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "162"}, {"groupId": "BG001", "value": "156"}, {"groupId": "BG002", "value": "160"}, {"groupId": "BG003", "value": "162"}, {"groupId": "BG004", "value": "640"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "51", "spread": "11.6"}, {"groupId": "BG001", "value": "52", "spread": "12.7"}, {"groupId": "BG002", "value": "53", "spread": "11.5"}, {"groupId": "BG003", "value": "54", "spread": "11.1"}, {"groupId": "BG004", "value": "52", "spread": "11.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "107"}, {"groupId": "BG001", "value": "113"}, {"groupId": "BG002", "value": "104"}, {"groupId": "BG003", "value": "120"}, {"groupId": "BG004", "value": "444"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "56"}, {"groupId": "BG003", "value": "42"}, {"groupId": "BG004", "value": "196"}]}]}]}, {"title": "FEV1 pre-bronchodilator", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "percentage of predicted normal", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "63.74", "lowerLimit": "30.11", "upperLimit": "85.41"}, {"groupId": "BG001", "value": "66.35", "lowerLimit": "29.92", "upperLimit": "113.57"}, {"groupId": "BG002", "value": "65.76", "lowerLimit": "32.57", "upperLimit": "123.86"}, {"groupId": "BG003", "value": "61.58", "lowerLimit": "31.13", "upperLimit": "84.86"}, {"groupId": "BG004", "value": "64.93", "lowerLimit": "29.92", "upperLimit": "123.86"}]}]}]}, {"title": "FEV1 post-bronchodilator", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "percentage of predicted normal", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "74.34", "lowerLimit": "32.33", "upperLimit": "105.44"}, {"groupId": "BG001", "value": "77.95", "lowerLimit": "30.38", "upperLimit": "112.83"}, {"groupId": "BG002", "value": "76.31", "lowerLimit": "34.88", "upperLimit": "112.89"}, {"groupId": "BG003", "value": "72.19", "lowerLimit": "31.26", "upperLimit": "111.88"}, {"groupId": "BG004", "value": "75.22", "lowerLimit": "30.38", "upperLimit": "112.89"}]}]}]}, {"title": "Reversibility", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage change", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "18.73", "spread": "20.617"}, {"groupId": "BG001", "value": "16.05", "spread": "15.580"}, {"groupId": "BG002", "value": "18.41", "spread": "20.574"}, {"groupId": "BG003", "value": "18.45", "spread": "16.342"}, {"groupId": "BG004", "value": "17.93", "spread": "18.438"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Rate of Severe Asthma Exacerbations During 6 Months", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Exacerbations per 6 month", "timeFrame": "From start of treatment up to 6 months", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "161"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "156"}, {"groupId": "OG003", "value": "159"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.31", "lowerLimit": "0.20", "upperLimit": "0.50"}, {"groupId": "OG001", "value": "0.31", "lowerLimit": "0.19", "upperLimit": "0.49"}, {"groupId": "OG002", "value": "0.26", "lowerLimit": "0.16", "upperLimit": "0.42"}, {"groupId": "OG003", "value": "0.20", "lowerLimit": "0.12", "upperLimit": "0.33"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.119", "pValueComment": "2-sided p-value", "statisticalMethod": "Poisson regression", "statisticalComment": "Correction for overdispersion made by Pearson chi-square", "paramType": "Risk Ratio (RR)", "paramValue": "1.56", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.98", "ciUpperLimit": "2.49", "estimateComment": "AZD5069 45 mg BID vs Placebo"}, {"groupIds": ["OG001", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.141", "pValueComment": "2-sided", "statisticalMethod": "Poisson Regression", "statisticalComment": "Correction for overdispersion made by Pearson chi-square", "paramType": "Risk Ratio (RR)", "paramValue": "1.53", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.95", "ciUpperLimit": "2.46", "estimateComment": "AZD5069 15 mg BID vs Placebo"}, {"groupIds": ["OG002", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.397", "pValueComment": "2-sided", "statisticalMethod": "Poisson Regression", "statisticalComment": "Correction for overdispersion made by Pearson chi-square", "paramType": "Risk Ratio (RR)", "paramValue": "1.29", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.79", "ciUpperLimit": "2.11", "estimateComment": "AZD5069 5 mg BID vs Placebo"}]}, {"type": "SECONDARY", "title": "Rate of Asthma-specific Hospital Admission/Intensive Care Unit Admissions During 6 Months", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Exacerbations per 6 month", "timeFrame": "From start of treatment up to 6 months", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "161"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "156"}, {"groupId": "OG003", "value": "159"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.04", "lowerLimit": "0.01", "upperLimit": "0.14"}, {"groupId": "OG001", "value": "0.02", "lowerLimit": "0.00", "upperLimit": "0.09"}, {"groupId": "OG002", "value": "0.02", "lowerLimit": "0.02", "upperLimit": "0.09"}, {"groupId": "OG003", "value": "0.02", "lowerLimit": "0.01", "upperLimit": "0.09"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Days of Asthma-specific Hospital Admission/Intensive Care Unit Admissions", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Days", "timeFrame": "From start of treatment up to 6 months", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "161"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "156"}, {"groupId": "OG003", "value": "159"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.54", "lowerLimit": "0.26", "upperLimit": "1.12"}, {"groupId": "OG001", "value": "0.82", "lowerLimit": "0.38", "upperLimit": "1.77"}, {"groupId": "OG002", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "0.01"}, {"groupId": "OG003", "value": "0.08", "lowerLimit": "0.03", "upperLimit": "0.23"}]}]}]}, {"type": "SECONDARY", "title": "Total Number of Days on Oral Cortecosteroids, Due to a Worsening of Asthma Symptoms", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Days", "timeFrame": "From start of treatment up to 6 months", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "161"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "156"}, {"groupId": "OG003", "value": "159"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.38", "lowerLimit": "1.33", "upperLimit": "4.26"}, {"groupId": "OG001", "value": "2.43", "lowerLimit": "1.33", "upperLimit": "4.45"}, {"groupId": "OG002", "value": "2.74", "lowerLimit": "1.42", "upperLimit": "5.29"}, {"groupId": "OG003", "value": "1.55", "lowerLimit": "0.80", "upperLimit": "3.00"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 2 Weeks Measurement of Pre-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at two weeks are included in the analysis", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "Baseline (Day 0) and 2 weeks after Day 0", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "145"}, {"groupId": "OG002", "value": "149"}, {"groupId": "OG003", "value": "155"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "lowerLimit": "0.06", "upperLimit": "0.20"}, {"groupId": "OG001", "value": "0.07", "lowerLimit": "0.00", "upperLimit": "0.14"}, {"groupId": "OG002", "value": "0.09", "lowerLimit": "0.02", "upperLimit": "0.16"}, {"groupId": "OG003", "value": "0.12", "lowerLimit": "0.05", "upperLimit": "0.19"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 1 Month Measurement of Pre-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at one month are included in the analysis", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "Baseline (Day 0) and 1 month after Day 0", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "146"}, {"groupId": "OG002", "value": "146"}, {"groupId": "OG003", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.14", "lowerLimit": "0.07", "upperLimit": "0.21"}, {"groupId": "OG001", "value": "0.08", "lowerLimit": "0.01", "upperLimit": "0.16"}, {"groupId": "OG002", "value": "0.09", "lowerLimit": "0.02", "upperLimit": "0.16"}, {"groupId": "OG003", "value": "0.09", "lowerLimit": "0.02", "upperLimit": "0.16"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 2 Months Measurement of Pre-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at two months are included in the analysis", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "Baseline (Day 0) and 2 months after Day 0", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}, {"groupId": "OG001", "value": "143"}, {"groupId": "OG002", "value": "145"}, {"groupId": "OG003", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "lowerLimit": "0.06", "upperLimit": "0.20"}, {"groupId": "OG001", "value": "0.08", "lowerLimit": "0.01", "upperLimit": "0.16"}, {"groupId": "OG002", "value": "0.07", "lowerLimit": "-0.01", "upperLimit": "0.14"}, {"groupId": "OG003", "value": "0.12", "lowerLimit": "0.05", "upperLimit": "0.19"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 3 Months Measurement of Pre-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at three months are included in the analysis", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "Baseline (Day 0) and 3 months after Day 0", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "142"}, {"groupId": "OG002", "value": "145"}, {"groupId": "OG003", "value": "149"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.10", "lowerLimit": "0.03", "upperLimit": "0.18"}, {"groupId": "OG001", "value": "0.11", "lowerLimit": "0.04", "upperLimit": "0.18"}, {"groupId": "OG002", "value": "0.06", "lowerLimit": "-0.02", "upperLimit": "0.13"}, {"groupId": "OG003", "value": "0.06", "lowerLimit": "-0.01", "upperLimit": "0.13"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 4 Months Measurement of Pre-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at four months are included in the analysis", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "Baseline (Day 0) and 4 months after Day 0", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "142"}, {"groupId": "OG002", "value": "146"}, {"groupId": "OG003", "value": "148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.17", "lowerLimit": "0.09", "upperLimit": "0.24"}, {"groupId": "OG001", "value": "0.17", "lowerLimit": "0.09", "upperLimit": "0.24"}, {"groupId": "OG002", "value": "0.14", "lowerLimit": "0.06", "upperLimit": "0.21"}, {"groupId": "OG003", "value": "0.16", "lowerLimit": "0.08", "upperLimit": "0.23"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 6 Months Measurement of Pre-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at six months are included in the analysis", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "Baseline (Day 0) and 6 months after Day 0", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "144"}, {"groupId": "OG001", "value": "140"}, {"groupId": "OG002", "value": "145"}, {"groupId": "OG003", "value": "149"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.14", "lowerLimit": "0.06", "upperLimit": "0.21"}, {"groupId": "OG001", "value": "0.09", "lowerLimit": "0.01", "upperLimit": "0.16"}, {"groupId": "OG002", "value": "0.10", "lowerLimit": "0.03", "upperLimit": "0.18"}, {"groupId": "OG003", "value": "0.11", "lowerLimit": "0.04", "upperLimit": "0.18"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 2 Weeks Measurement of Post-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at two weeks are included in the analysis", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "Baseline (Day 0) and 2 weeks after Day 0", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "139"}, {"groupId": "OG002", "value": "143"}, {"groupId": "OG003", "value": "146"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "lowerLimit": "0.01", "upperLimit": "0.11"}, {"groupId": "OG001", "value": "0.05", "lowerLimit": "-0.01", "upperLimit": "0.10"}, {"groupId": "OG002", "value": "0.03", "lowerLimit": "-0.02", "upperLimit": "0.09"}, {"groupId": "OG003", "value": "0.03", "lowerLimit": "-0.02", "upperLimit": "0.09"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 1 Month Measurement of Post-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at one month are included in the analysis", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "Baseline (Day 0) and 1 month after Day 0", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "144"}, {"groupId": "OG001", "value": "140"}, {"groupId": "OG002", "value": "141"}, {"groupId": "OG003", "value": "142"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "lowerLimit": "0.01", "upperLimit": "0.12"}, {"groupId": "OG001", "value": "0.05", "lowerLimit": "0.00", "upperLimit": "0.11"}, {"groupId": "OG002", "value": "0.03", "lowerLimit": "-0.03", "upperLimit": "0.09"}, {"groupId": "OG003", "value": "0.03", "lowerLimit": "-0.03", "upperLimit": "0.08"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 2 Months Measurement of Post-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at two months are included in the analysis", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "Baseline (Day 0) and 2 months after Day 0", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "138"}, {"groupId": "OG002", "value": "141"}, {"groupId": "OG003", "value": "142"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "lowerLimit": "-0.02", "upperLimit": "0.09"}, {"groupId": "OG001", "value": "0.04", "lowerLimit": "-0.02", "upperLimit": "0.10"}, {"groupId": "OG002", "value": "0.01", "lowerLimit": "-0.05", "upperLimit": "0.07"}, {"groupId": "OG003", "value": "0.02", "lowerLimit": "-0.04", "upperLimit": "0.08"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 3 Months Measurement of Post-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at three months are included in the analysis", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "Baseline (Day 0) and 3 months after Day 0", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "138"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "141"}, {"groupId": "OG003", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.04", "lowerLimit": "-0.02", "upperLimit": "0.10"}, {"groupId": "OG001", "value": "0.04", "lowerLimit": "-0.02", "upperLimit": "0.10"}, {"groupId": "OG002", "value": "-0.00", "lowerLimit": "-0.06", "upperLimit": "0.06"}, {"groupId": "OG003", "value": "-0.01", "lowerLimit": "-0.07", "upperLimit": "0.05"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 4 Months Measurement of Post-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at four months are included in the analysis", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "Baseline (Day 0) and 4 months after Day 0", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "141"}, {"groupId": "OG003", "value": "141"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "lowerLimit": "-0.00", "upperLimit": "0.12"}, {"groupId": "OG001", "value": "0.06", "lowerLimit": "0.00", "upperLimit": "0.13"}, {"groupId": "OG002", "value": "0.03", "lowerLimit": "-0.03", "upperLimit": "0.10"}, {"groupId": "OG003", "value": "0.03", "lowerLimit": "-0.03", "upperLimit": "0.10"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 6 Months Measurement of Post-bronchodilator FEV1", "description": "Only patients with both a non-missing value at baseline and visit at six months are included in the analysis", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "L", "timeFrame": "Baseline (Day 0) and 6 months after Day 0", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "139"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "142"}, {"groupId": "OG003", "value": "145"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "lowerLimit": "0.01", "upperLimit": "0.12"}, {"groupId": "OG001", "value": "0.02", "lowerLimit": "-0.03", "upperLimit": "0.08"}, {"groupId": "OG002", "value": "0.04", "lowerLimit": "-0.02", "upperLimit": "0.10"}, {"groupId": "OG003", "value": "-0.01", "lowerLimit": "-0.07", "upperLimit": "0.05"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Overall Mean of Treatment Period in ACQ-5 (Asthma Control Questionnaire, 5-item Version) Total Score", "description": "The ACQ-5 is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze. Each item is graded on a scale of 0-6 and the questions are equally weighted. The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Units on a scale]", "timeFrame": "Baseline (Day 0), Treatment Period (1,2,3,4, and 6 months)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "149"}, {"groupId": "OG002", "value": "149"}, {"groupId": "OG003", "value": "156"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.68", "lowerLimit": "-0.83", "upperLimit": "-0.52"}, {"groupId": "OG001", "value": "-0.66", "lowerLimit": "-0.82", "upperLimit": "-0.51"}, {"groupId": "OG002", "value": "-0.64", "lowerLimit": "-0.80", "upperLimit": "-0.48"}, {"groupId": "OG003", "value": "-0.70", "lowerLimit": "-0.86", "upperLimit": "-0.55"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Presenting Improvement From Baseline to End of Treatment Period in ACQ-5 (Asthma Control Questionnaire, 5-item Version)", "description": "The ACQ-5 is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze. Each item is graded on a scale of 0-6 and the questions are equally weighted. The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants with improvement", "timeFrame": "Baseline (Day 0) and 6 months after Day 0", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "133"}, {"groupId": "OG001", "value": "134"}, {"groupId": "OG002", "value": "134"}, {"groupId": "OG003", "value": "141"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "88"}, {"groupId": "OG002", "value": "73"}, {"groupId": "OG003", "value": "69"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Overall Mean of Treatment Period in AQLQ(S) (Asthma Quality of Life Questionnaire Standardised Version) Overall Score", "description": "The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments in asthma. Patients are asked to score each item on a 7-point scale based on the experience of last 2 weeks. The overall AQLQ score is the mean response to all 32 questions. Therefore, the possible highest score (better) would be 7 and the lowest (worse) would be 1. Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and \\> 1.5 as marked clinically important differences for any individual domain or for the overall summary score.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Overall Score", "timeFrame": "Baseline (Day 0), Treatment Period (1,3, and 6 months)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "152"}, {"groupId": "OG001", "value": "145"}, {"groupId": "OG002", "value": "145"}, {"groupId": "OG003", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.50", "lowerLimit": "0.36", "upperLimit": "0.65"}, {"groupId": "OG001", "value": "0.46", "lowerLimit": "0.31", "upperLimit": "0.61"}, {"groupId": "OG002", "value": "0.52", "lowerLimit": "0.37", "upperLimit": "0.67"}, {"groupId": "OG003", "value": "0.52", "lowerLimit": "0.38", "upperLimit": "0.67"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Presenting Improvement From Baseline to End of Treatment Period in AQLQ(S) (Asthma Quality of Life Questionnaire Standardised Version) Overall Score", "description": "The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments in asthma. Patients are asked to score each item on a 7-point scale based on the experience of last 2 weeks. The overall AQLQ score is the mean response to all 32 questions. Therefore, the possible highest score (better) would be 7 and the lowest (worse) would be 1. Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and \\> 1.5 as marked clinically important differences for any individual domain or for the overall summary score.", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants with improvement", "timeFrame": "Baseline (Day 0) and 6 months after Day 0", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "132"}, {"groupId": "OG002", "value": "131"}, {"groupId": "OG003", "value": "139"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "69"}, {"groupId": "OG003", "value": "62"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 1 to Day 28) for Astma Symptom Free Days", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Asthma symptom free days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 1 to 28)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "160"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "156"}, {"groupId": "OG003", "value": "159"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "lowerLimit": "-3.4", "upperLimit": "2.7"}, {"groupId": "OG001", "value": "1.6", "lowerLimit": "-1.5", "upperLimit": "4.6"}, {"groupId": "OG002", "value": "1.2", "lowerLimit": "-2.0", "upperLimit": "4.3"}, {"groupId": "OG003", "value": "1.1", "lowerLimit": "-1.9", "upperLimit": "4.1"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 29 to Day 56) for Astma Symptom Free Days", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "symptom free days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 29 to 56)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "158"}, {"groupId": "OG001", "value": "148"}, {"groupId": "OG002", "value": "152"}, {"groupId": "OG003", "value": "155"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "lowerLimit": "-4.3", "upperLimit": "4.7"}, {"groupId": "OG001", "value": "2.6", "lowerLimit": "-2.0", "upperLimit": "7.1"}, {"groupId": "OG002", "value": "3.4", "lowerLimit": "-1.2", "upperLimit": "8.1"}, {"groupId": "OG003", "value": "3.1", "lowerLimit": "-1.4", "upperLimit": "7.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 57 to Day 84) for Asthma Symptom Free Days", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "symptom free days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 57 to 84)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "146"}, {"groupId": "OG002", "value": "149"}, {"groupId": "OG003", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.4", "lowerLimit": "-3.4", "upperLimit": "6.3"}, {"groupId": "OG001", "value": "4.3", "lowerLimit": "-0.6", "upperLimit": "9.3"}, {"groupId": "OG002", "value": "3.0", "lowerLimit": "-2.1", "upperLimit": "8.0"}, {"groupId": "OG003", "value": "4.0", "lowerLimit": "-0.9", "upperLimit": "8.9"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 85 to End of Treatment [6 Months]) for Asthma Symptom Free Days", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "symptom free days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Day 85 to 6 months)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "152"}, {"groupId": "OG001", "value": "145"}, {"groupId": "OG002", "value": "148"}, {"groupId": "OG003", "value": "151"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.6", "lowerLimit": "-2.5", "upperLimit": "7.8"}, {"groupId": "OG001", "value": "5.6", "lowerLimit": "0.5", "upperLimit": "10.7"}, {"groupId": "OG002", "value": "3.9", "lowerLimit": "-1.3", "upperLimit": "9.2"}, {"groupId": "OG003", "value": "4.4", "lowerLimit": "-0.7", "upperLimit": "9.5"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 1 to Day 28) for Asthma Control Days", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "asthma control days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 1 to 28)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "160"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "156"}, {"groupId": "OG003", "value": "159"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "lowerLimit": "-3.9", "upperLimit": "1.6"}, {"groupId": "OG001", "value": "1.7", "lowerLimit": "-1.1", "upperLimit": "4.6"}, {"groupId": "OG002", "value": "1.2", "lowerLimit": "-1.7", "upperLimit": "4.1"}, {"groupId": "OG003", "value": "0.9", "lowerLimit": "-1.8", "upperLimit": "3.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 29 to Day 56) for Asthma Control Days", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "asthma control days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 29 to 56)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "158"}, {"groupId": "OG001", "value": "148"}, {"groupId": "OG002", "value": "151"}, {"groupId": "OG003", "value": "155"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "lowerLimit": "-4.2", "upperLimit": "4.0"}, {"groupId": "OG001", "value": "3.5", "lowerLimit": "-0.7", "upperLimit": "7.7"}, {"groupId": "OG002", "value": "2.7", "lowerLimit": "-4.2", "upperLimit": "4.0"}, {"groupId": "OG003", "value": "2.8", "lowerLimit": "-1.4", "upperLimit": "6.9"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 57 to Day 84) for Asthma Control Days", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "asthma control days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 57 to 84)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "146"}, {"groupId": "OG002", "value": "149"}, {"groupId": "OG003", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.9", "lowerLimit": "-3.8", "upperLimit": "5.6"}, {"groupId": "OG001", "value": "4.7", "lowerLimit": "-0.0", "upperLimit": "9.4"}, {"groupId": "OG002", "value": "3.2", "lowerLimit": "-1.6", "upperLimit": "8.1"}, {"groupId": "OG003", "value": "2.9", "lowerLimit": "-1.8", "upperLimit": "7.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 85 to End of Treatment [6 Months]) for Asthma Control Days", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "asthma control days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 85 to 6 months", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "152"}, {"groupId": "OG001", "value": "145"}, {"groupId": "OG002", "value": "148"}, {"groupId": "OG003", "value": "151"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.4", "lowerLimit": "-3.4", "upperLimit": "6.2"}, {"groupId": "OG001", "value": "5.7", "lowerLimit": "0.9", "upperLimit": "10.5"}, {"groupId": "OG002", "value": "3.9", "lowerLimit": "-1.0", "upperLimit": "8.8"}, {"groupId": "OG003", "value": "2.4", "lowerLimit": "-2.3", "upperLimit": "7.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 1 to Day 28) for Use of Rescue Medication Free Days", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "rescue medication free days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 1 to 28)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "160"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "156"}, {"groupId": "OG003", "value": "159"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.0", "lowerLimit": "-0.6", "upperLimit": "8.6"}, {"groupId": "OG001", "value": "8.3", "lowerLimit": "3.6", "upperLimit": "13.0"}, {"groupId": "OG002", "value": "6.8", "lowerLimit": "2.0", "upperLimit": "11.5"}, {"groupId": "OG003", "value": "9.5", "lowerLimit": "4.9", "upperLimit": "14.1"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 29 to Day 56) for Use of Rescue Medication Free Days", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "rescue medication free days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 29 to 56)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "158"}, {"groupId": "OG001", "value": "148"}, {"groupId": "OG002", "value": "150"}, {"groupId": "OG003", "value": "155"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.7", "lowerLimit": "4.6", "upperLimit": "16.8"}, {"groupId": "OG001", "value": "17.6", "lowerLimit": "11.4", "upperLimit": "23.8"}, {"groupId": "OG002", "value": "15.4", "lowerLimit": "9.1", "upperLimit": "21.8"}, {"groupId": "OG003", "value": "16.4", "lowerLimit": "10.3", "upperLimit": "22.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 57 to Day 84) for Use of Rescue Medication Free Days", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "rescue medication free days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 57 to 84)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "146"}, {"groupId": "OG002", "value": "147"}, {"groupId": "OG003", "value": "153"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.3", "lowerLimit": "5.7", "upperLimit": "18.9"}, {"groupId": "OG001", "value": "19.2", "lowerLimit": "12.6", "upperLimit": "25.9"}, {"groupId": "OG002", "value": "19.8", "lowerLimit": "13.0", "upperLimit": "26.6"}, {"groupId": "OG003", "value": "18.7", "lowerLimit": "12.1", "upperLimit": "25.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 85 to End of Treatment [6 Months]) for Use of Rescue Medication Free Days", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "rescue medication free days", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 85 to 6 months)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "152"}, {"groupId": "OG001", "value": "145"}, {"groupId": "OG002", "value": "147"}, {"groupId": "OG003", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.8", "lowerLimit": "9.0", "upperLimit": "22.7"}, {"groupId": "OG001", "value": "23.1", "lowerLimit": "16.2", "upperLimit": "29.9"}, {"groupId": "OG002", "value": "21.2", "lowerLimit": "14.2", "upperLimit": "28.2"}, {"groupId": "OG003", "value": "20.0", "lowerLimit": "13.2", "upperLimit": "26.8"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 1 to Day 28) for Night Time Awakenings Due to Asthma Symptoms", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "night time awakenings", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Days 1 to 28)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "161"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "156"}, {"groupId": "OG003", "value": "159"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.1", "lowerLimit": "-14.6", "upperLimit": "-5.5"}, {"groupId": "OG001", "value": "-11.1", "lowerLimit": "-15.7", "upperLimit": "-6.5"}, {"groupId": "OG002", "value": "-11.3", "lowerLimit": "-16.0", "upperLimit": "-6.6"}, {"groupId": "OG003", "value": "-8.9", "lowerLimit": "-13.4", "upperLimit": "-4.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 29 to Day 56) for Night Time Awakenings Due to Asthma Symptoms", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "night time awakenings", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Day 29 to Day 56)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "158"}, {"groupId": "OG001", "value": "148"}, {"groupId": "OG002", "value": "152"}, {"groupId": "OG003", "value": "156"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.2", "lowerLimit": "-20.7", "upperLimit": "-9.8"}, {"groupId": "OG001", "value": "-19.0", "lowerLimit": "-24.5", "upperLimit": "-13.5"}, {"groupId": "OG002", "value": "-18.2", "lowerLimit": "-23.8", "upperLimit": "-12.6"}, {"groupId": "OG003", "value": "-15.2", "lowerLimit": "-20.7", "upperLimit": "-9.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 57 to Day 84) for Night Time Awakenings Due to Asthma Symptoms", "populationDescription": "full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "night time awakenings", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Day 57 to Day 84)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "155"}, {"groupId": "OG001", "value": "146"}, {"groupId": "OG002", "value": "149"}, {"groupId": "OG003", "value": "154"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-17.6", "lowerLimit": "-23.2", "upperLimit": "-11.9"}, {"groupId": "OG001", "value": "-19.8", "lowerLimit": "-25.5", "upperLimit": "-14.0"}, {"groupId": "OG002", "value": "-22.1", "lowerLimit": "-27.9", "upperLimit": "-16.2"}, {"groupId": "OG003", "value": "-16.7", "lowerLimit": "-22.4", "upperLimit": "-11.0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Treatment Period (Day 85 to End of Treatment [6 Months]) for Night Time Awakenings Due to Asthma Symptoms", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "night time awakenings", "timeFrame": "Baseline (last 14 days before randomization) and Treatment Period (Day 85 to 6 months)", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "145"}, {"groupId": "OG002", "value": "148"}, {"groupId": "OG003", "value": "152"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-22.8", "lowerLimit": "-28.7", "upperLimit": "-17.0"}, {"groupId": "OG001", "value": "-25.5", "lowerLimit": "-31.3", "upperLimit": "-19.6"}, {"groupId": "OG002", "value": "-25.3", "lowerLimit": "-31.3", "upperLimit": "-19.3"}, {"groupId": "OG003", "value": "-21.8", "lowerLimit": "-27.7", "upperLimit": "-16.0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Well Controlled Asthma Weeks at Baseline", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Last 2 weeks before randomization", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "160"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "156"}, {"groupId": "OG003", "value": "159"}]}], "classes": [{"title": "0 Well-controlled asthma weeks Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "150"}, {"groupId": "OG003", "value": "152"}]}]}, {"title": "1 Well-controlled asthma weeks Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "7"}]}]}, {"title": "2 Well-controlled asthma weeks Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Well Controlled Asthma Weeks During Treatment", "populationDescription": "Full Analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "well controlled asthma weeks", "timeFrame": "Day 1to end of the 6 months treatment period", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "162"}, {"groupId": "OG001", "value": "156"}, {"groupId": "OG002", "value": "160"}, {"groupId": "OG003", "value": "158"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.7", "spread": "4.38"}, {"groupId": "OG001", "value": "1.9", "spread": "4.78"}, {"groupId": "OG002", "value": "2.4", "spread": "5.38"}, {"groupId": "OG003", "value": "2.3", "spread": "5.27"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Uncontrolled Persistent Asthma Weeks at Baseline", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Last 2 weeks before randomization", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "160"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "156"}, {"groupId": "OG003", "value": "158"}]}], "classes": [{"title": "0 uncontrolled persistent asthma weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "26"}, {"groupId": "OG003", "value": "27"}]}]}, {"title": "1 uncontrolled persistent asthma weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "39"}, {"groupId": "OG002", "value": "34"}, {"groupId": "OG003", "value": "36"}]}]}, {"title": "2 uncontrolled persistent asthma weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "96"}, {"groupId": "OG002", "value": "96"}, {"groupId": "OG003", "value": "95"}]}]}]}, {"type": "SECONDARY", "title": "Number of Uncontrolled Persistent Asthma Weeks During Treatment", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "uncontrolled persistent asthma weeks", "timeFrame": "Day 1 to end of the 6 months treatment period", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "162"}, {"groupId": "OG001", "value": "156"}, {"groupId": "OG002", "value": "160"}, {"groupId": "OG003", "value": "157"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11.0", "spread": "10.0"}, {"groupId": "OG001", "value": "10.7", "spread": "10.02"}, {"groupId": "OG002", "value": "10.4", "spread": "9.84"}, {"groupId": "OG003", "value": "10.9", "spread": "9.89"}]}]}]}, {"type": "SECONDARY", "title": "Mean Plasma Concentration of AZD5069 at Day 7", "populationDescription": "PK analysis set", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "(nmol/L)", "timeFrame": "Day 7", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "147"}, {"groupId": "OG002", "value": "144"}, {"groupId": "OG003", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "235.0", "spread": "1525.49"}, {"groupId": "OG001", "value": "69.9", "spread": "717.83"}, {"groupId": "OG002", "value": "25.4", "spread": "511.02"}]}]}]}, {"type": "SECONDARY", "title": "Mean Plasma Concentration of AZD5069 at 1 Month", "populationDescription": "PK analysis set", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "(nmol/L)", "timeFrame": "at 1 month", "groups": [{"id": "OG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo oral capsules self-administred twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "139"}, {"groupId": "OG003", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "152.2", "spread": "11200.64"}, {"groupId": "OG001", "value": "76.4", "spread": "788.17"}, {"groupId": "OG002", "value": "25.8", "spread": "449.02"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "timeFrame": "12 months", "eventGroups": [{"id": "EG000", "title": "AZD5069 45 mg BID", "description": "AZD5069 oral capsules self-administered twice daily", "seriousNumAffected": 14, "seriousNumAtRisk": 161, "otherNumAffected": 86, "otherNumAtRisk": 161}, {"id": "EG001", "title": "AZD5069 15 mg BID", "description": "AZD5069 oral capsules self-administered twice daily", "seriousNumAffected": 8, "seriousNumAtRisk": 153, "otherNumAffected": 68, "otherNumAtRisk": 153}, {"id": "EG002", "title": "AZD5069 5 mg BID", "description": "AZD5069 oral capsules self-administered twice daily", "seriousNumAffected": 7, "seriousNumAtRisk": 156, "otherNumAffected": 74, "otherNumAtRisk": 156}, {"id": "EG003", "title": "Placebo", "description": "Placebo oral capsules self-administered twice daily", "seriousNumAffected": 13, "seriousNumAtRisk": 159, "otherNumAffected": 96, "otherNumAtRisk": 159}], "seriousEvents": [{"term": "PNEUMONIA", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 159}]}, {"term": "RENAL CANCER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 159}]}, {"term": "LUNG NEOPLASM MALIGNANT", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 159}]}, {"term": "UTERINE LEIOMYOMA", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 159}]}, {"term": "ABDOMINAL ABSCESS", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "HELICOBACTER GASTRITIS", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "LOWER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "LOWER RESPIRATORY TRACT INFECTION BACTERIAL", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "SALMONELLOSIS", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "STREPTOCOCCAL SEPSIS", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "VIRAL UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "ACUTE TONSILLITIS", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 159}]}, {"term": "NEUTROPENIA", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "CRITICAL ILLNESS POLYNEUROPATHY", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "ISCHAEMIC STROKE", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 159}]}, {"term": "ATRIAL FIBRILLATION", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 159}]}, {"term": "CORONARY ARTERY DISEASE", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 159}]}, {"term": "PERIPHERAL EMBOLISM", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "HYPERTENSION", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 159}]}, {"term": "ASTHMA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 159}]}, {"term": "ASTHMATIC CRISIS", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "BARRETTS OESOPHAGUS", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "GASTRITIS", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "HIATUS HERNIA", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "ABDOMINAL HERNIA", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 159}]}, {"term": "INGUINAL HERNIA", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 159}]}, {"term": "CHOLECYSTITIS CHRONIC", "organSystem": "Hepatobiliary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 159}]}, {"term": "CHOLELITHIASIS", "organSystem": "Hepatobiliary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "ARTHRALGIA", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "CALCULUS URETERIC", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 159}]}, {"term": "OVARIAN CYST", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "PSEUDOHYPOPARATHYROIDISM", "organSystem": "Congenital, familial and genetic disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "ALANINE AMINOTRANSFERASE INCREASED", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "PATELLA FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}], "otherEvents": [{"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 18, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 31, "numAtRisk": 159}]}, {"term": "BACK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 159}]}, {"term": "ARTHRALGIA", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 159}]}, {"term": "ABDOMINAL PAIN UPPER", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 159}]}, {"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 159}]}, {"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 159}]}, {"term": "GASTROOESOPHAGEAL REFLUX DISEASE", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 159}]}, {"term": "COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 15, "numAtRisk": 159}]}, {"term": "BRONCHITIS", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 10, "numAtRisk": 159}]}, {"term": "PHARYNGITIS", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 159}]}, {"term": "VIRAL UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 159}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 159}]}, {"term": "INFLUENZA", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 159}]}, {"term": "PNEUMONIA", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 159}]}, {"term": "RHINITIS", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "SINUSITIS", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 159}]}, {"term": "LOWER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 159}]}, {"term": "URINARY TRACT INFECTION", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 159}]}, {"term": "GASTROENTERITIS", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 159}]}, {"term": "Other", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 159}]}, {"term": "Other", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 159}]}, {"term": "Other", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 159}]}, {"term": "Other", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 159}]}, {"term": "Other", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 159}]}, {"term": "ASTHMA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 161}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 156}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 159}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Medical Science Director Bengt Larsson", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}}, "hasResults": true}